A blood atlas of COVID-19 defines hallmarks of disease severity and specificity



COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium, , Ahern, David, Ai, Zhichao, Ainsworth, Mark, Allan, Chris, Allcock, Alice, Ansari, Azim ORCID: 0000-0003-2790-8353, Arancibia-Carcamo, Carolina, Aschenbrenner, Dominik, Attar, Moustafa ORCID: 0000-0003-4116-1276
et al (show 194 more authors) (2021) A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.

Access the full-text of this item by clicking on the Open Access link.

Abstract

<h4>Summary</h4> Treatment of severe COVID-19 is currently limited by clinical heterogeneity and incomplete understanding of potentially druggable immune mediators of disease. To advance this, we present a comprehensive multi-omic blood atlas in patients with varying COVID-19 severity and compare with influenza, sepsis and healthy volunteers. We identify immune signatures and correlates of host response. Hallmarks of disease severity revealed cells, their inflammatory mediators and networks as potential therapeutic targets, including progenitor cells and specific myeloid and lymphocyte subsets, features of the immune repertoire, acute phase response, metabolism and coagulation. Persisting immune activation involving AP-1/p38MAPK was a specific feature of COVID-19. The plasma proteome enabled sub-phenotyping into patient clusters, predictive of severity and outcome. Tensor and matrix decomposition of the overall dataset revealed feature groupings linked with disease severity and specificity. Our systems-based integrative approach and blood atlas will inform future drug development, clinical trial design and personalised medicine approaches for COVID-19.

Item Type: Article
Uncontrolled Keywords: COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Infection, Veterinary and Ecological Sciences
Depositing User: Symplectic Admin
Date Deposited: 30 Sep 2021 08:03
Last Modified: 08 Sep 2022 18:12
DOI: 10.1101/2021.05.11.21256877
Open Access URL: https://www.medrxiv.org/content/10.1101/2021.05.11...
URI: https://livrepository.liverpool.ac.uk/id/eprint/3138710